Eisai Co., Ltd. engages in the manufacture and marketing of pharmaceuticals, such as prescription pharmaceuticals, consumer health care products, and diagnostics pharmaceuticals. The company also offers food additives, chemicals, pharmaceutical production machinery, and equipment. It has operations in Japan, North America, Europe, and Asia. Products The company's prescription pharmaceuticals include Aricept for Alzheimer’s disease treatment; Actonel for osteoporosis treatment; Azeptin, an antiallergic agent; Iomeron, a nonionic contrast medium; Glakay for osteoporosis treatment; Glucagon G Novo, a genetically engineered glucagon preparation; Cleactor, a thrombolytic agent; Coretec, an agent for acute heart failure; Selbex for gastritis/gastric ulcer treatment; Tambocor, an agent for tachyarrhythmia; Detantol R, a once-a-day a-1 blocking antihypertensive agent; Nitorol R, a long-acting isosorbide dinitrate preparation; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; ProHance, a nonionic contrast medium for MRI use; Maxalt, a 5-HT1B/1D receptor agonist for migraine treatment; Myonal, a muscle relaxant; Methycobal for peripheral neuropathy treatment; and Warfarin potassium tablets. The company's generic products include Amlodipine tablets (long-action calcium antagonist); Enalapril M tablets (long-acting ACE inhibitor); Domperidone tablets (gastroprokinetic drug); Felbinac tape (transdermal system anti-inflammatory analgesic drug); BlostarM tablets (famotidine tablets); Pranlukast tablets/ dry syrup (therapeutic drug for bronchial asthma); Meloxicam tablets (nonsteroidal anti-inflammatory/analgesic drug); and Loxoprofen tablets (analgesic/anti-inflammatory/antipyretic drug). The company's consumer health care products include Saclon for restoration of damaged stomach mucosa and acid neutralization; Sahne Cream, a medicated skin-care cream; Seabond, a denture adhesive; Skainar S tablets for Rhinitis, a medication for rhinitis; Selbelle tablets for stomach heaviness, heartburn, and overeating; Chocola BB Plus, a vitamin B2 supplement for alleviation of stomatitis and dermatitis; Chocola BB Lucent for eliminating skin blemishes and freckles with vitamin C and L-cysteine; Chocola BB Pure, an active-type vitamin B2 preparation with vitamins B6, B1, and C; Chocola BB Drink II, a vitamin B2 drink for alleviation of skin roughness and acne; Chocola BB Royal 2, a vitamin B2 drink with royal jelly and amino acids for extreme fatigue; Travelmin, a motion sickness remedy; Nabolin S, a mecobalamin (activated vitamin B12) preparation for alleviating stubborn stiff shoulders; Higuard, an agent for allergy-related rhinitis and skin problems; Ubiten S, an ubidecarenone (coenzyme Q10) preparation; and Juvelux, a natural vitamin E preparation. The company's diagnostic products include Picolumi PIVKA-II for the diagnosis of hepatocellular carcinoma with protein induced by vitamin K absence or antagonist II (PIVKA-II); Picolumi KL-6 for the diagnosis of interstitial pneumonia with sialylated carbohydrate antigen KL-6; Picolumi ucOC for the diagnosis of vitamin ucOC K insufficiency in osteoporosis with undercarboxylated osteocalcin (ucOC); Picolumi CA•RF for the diagnosis of rheumatoid arthritis with anti-agalactosyl IgG antibodies; PyloriTek Test Kit, a test for Heliobacter pyloriurease activity in gastric biopsy specimens; CoaguChek XS for determination of prothrombin time in whole blood; and G-Checker, a self-monitoring blood glucose system. Agreements The company has a licensing agreement with BioArctic Neuroscience AB for antibody treatment BAN2401 for Alzheimer’s disease. The company and Abbott Japan Co., Ltd. have a license agreement in Japan for additional indications for adalimumab, the fully human anti-TNF-a monoclonal antibody. The company has reached in-licensing agreement with Minophagen Pharmaceutical Co., Ltd., for liver disease/allergic disease agents Stronger Neo-Minophagen C and Glycyron tablets. The company also has a license agreement with Kissei Pharmaceutical Co., Ltd., to develop and commercialize insulin secretagogue Glufast in China. The company has an in-licensing agreement with Sepracor, Inc. for eszopiclone insomnia treatment in Japan. Acquisitions In January 2008, the company acquired MGI PHARMA, INC., a U.S.-based biopharmaceutical company focused on oncology and acute care that acquires, researches, develops, and commercializes proprietary products. Collaborations In September 2009, Eisai Co. Ltd. and the Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement for the clinical development of a new drug for the treatment of Chagas disease. Significant Events On October 26, 2009, Eisai Co. Ltd. and TSD Japan Inc. announced that they had concluded a license and joint development agreement for the development of denileukin diftitox (generic name) in Japan. Under the terms of the agreement, Eisai shall grant TSD the exclusive right to co-develop the drug in Japan, and Eisai would retain the right to market the product once marketing authorisation has been granted. On October 30, 2009, Quintiles Limited announced a strategic alliance with Eisai Co. Ltd. to develop six potential oncology products in Eisai's R&D pipeline. History Eisai Co., Ltd. was founded in 1941.
eisai co ltd (4523:Tokyo)
Phone: 81 3 3817 3700
|Almirall SA||€15.33 EUR||+0.10|
|Nektar Therapeutics||$14.62 USD||+0.03|
|Salix Pharmaceuticals Ltd||$125.92 USD||-0.07|
|Synergy Health PLC||2,147 GBp||+48.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.